262 papers found
Refreshing results…
Checkpoint inhibitors in breast cancer – Current status
Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy
Frequent adaptive immune responses against arginase-1
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma
Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes
PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.
Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma and the potential benefit of anti-CD137 stimulation.
Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial
Missing publications? Read more about our data sources.